{"id":"magnevist-sh-l-451a","safety":{"commonSideEffects":[{"rate":null,"effect":"Gadolinium retention in tissues"},{"rate":null,"effect":"Nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1200431","moleculeType":"Small molecule","molecularWeight":"742.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Magnevist (gadopentetate dimeglumine) contains gadolinium, a paramagnetic metal ion that increases the relaxation rate of nearby water molecules, resulting in increased signal intensity on T1-weighted MRI images. This allows for improved visualization and differentiation of tissues and lesions during MRI examinations. The gadolinium is chelated with diethylenetriaminepentaacetic acid (DTPA) to improve safety and reduce toxicity.","oneSentence":"Magnevist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:39.598Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"MRI contrast enhancement for central nervous system imaging"},{"name":"MRI contrast enhancement for body imaging including cardiovascular and abdominal applications"}]},"trialDetails":[{"nctId":"NCT00681551","phase":"PHASE3","title":"Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-02","conditions":"Brain Neoplasms","enrollment":45},{"nctId":"NCT00652418","phase":"PHASE2","title":"Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-07","conditions":"Magnetic Resonance Angiography, Peripheral Vascular Diseases, Peripheral Arterial Diseases","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Magnevist (SH L 451A)","genericName":"Magnevist (SH L 451A)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Magnevist is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including cardiovascular and abdominal applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}